New infusion drug AION-301 aims to slow kidney disease progression

NCT ID NCT06721143

Recruiting now Disease control Sponsor: AION Healthspan, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether two infusions of AION-301 are safe and can reduce symptoms or slow the worsening of Stage 3 chronic kidney disease. About 36 adults will receive either AION-301 or a placebo, along with oral vitamins, and be followed for up to 24 months. The main goal is to check for side effects and see if the drug helps lower protein in the urine.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE STAGE 3 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC KIDNEY DISEASE STAGE 3

Contacts and locations

Locations

SouthCoast Research Center, Inc.
RECRUITING

Miami, Florida, 33136, United States
University of Miami, Leonard M. Miller School of Medicine
RECRUITING

Miami, Florida, 33136, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.